我的账号
产品 已被添加到您的购物车。
Detect Cancer Early

Stay One Step Ahead,
Detect Cancer Before It Grows

See Your Testing Options

Blood-based genetic screening reveals early warning signs across multiple cancers, even those not covered by standard checks.

99% specificity, minimizing false positives—95%+ in recent trials
~40–50% sensitivity for early-stage cancers (Stage I–III)
70% of detected cancers were types without standard screening methods
Detect Cancer Early

Blood-based genetic screening reveals early warning signs across multiple cancers, even those not covered by standard checks.

99% specificity, minimizing false positives—95%+ in recent trials
~40–50% sensitivity for early-stage cancers (Stage I–III)
70% of detected cancers were types without standard screening methods
Why Early Detection Matters

Early Detection Saves Lives

Early-stage breast cancer has a 99% five-year survival, but that drops below 32% if found late.
Early Detection
Detect cancers years before symptoms emerge
Hidden Cancers
Identify cancers standard screenings can’t catch—like ovarian or pancreatic
Better Outcomes
More treatment options and better outcomes when caught early
Survival Rate for 5 Years After Diagnosed
Unfortunately, the current blood test can detect only the later stages of cancer
Survival Rate for 5 Years After Diagnosed
Unfortunately, the current blood test can detect only the later stages of cancer
How It Works

Simple, Powerful, Personalized

步骤 1
Provide sample at home or clinic
步骤 2
Advanced AI-driven analysis spots cancer DNA
步骤 3
Get a clear result, including confidence and next steps
Featured Tests

Get Screened Early

CancerDetect™ – Multi Cancer Early Detection Test
  • Detects both common & rare cancers, with >0% sensitivity across 80+ cancer types
  • High specificity: >99% accuracy
  • Ideal for ages 40+, family history, or after previous treatment
Learn More
Diagnostic Test Performance Comparison
Test Specificity Sensitivity
Liquid Biopsy High (Approximately 90-99%) Variable (Approximately 60%-90% or higher in advanced cancer stages)
MRI High (Approximately 85%-95%) Approximately 80%-95%
CT Scan Moderate High (Approximately 75%-85%) Approximately 80%-90%
  • Liquid Biopsy tests are highly specific for detecting specific genetic mutations.
  • MRI and PET scans are sensitive in identifying anatomical and functional abnormalities associated with cancer and other medical conditions.
CancerDetect™ – Multi Cancer Early Detection Test
  • Detects both common & rare cancers, with >0% sensitivity across 80+ cancer types
  • High specificity: >99% accuracy
  • Ideal for ages 40+, family history, or after previous treatment
Learn More
Diagnostic Test Performance Comparison
Test Specificity Sensitivity
Liquid Biopsy High (Approximately 90-99%) Variable (Approximately 60%-90% or higher in advanced cancer stages)
MRI High (Approximately 85%-95%) Approximately 80%-95%
CT Scan Moderate High (Approximately 75%-85%) Approximately 80%-90%
  • Liquid Biopsy tests are highly specific for detecting specific genetic mutations.
  • MRI and PET scans are sensitive in identifying anatomical and functional abnormalities associated with cancer and other medical conditions.
SuperDNA Cancer Risk Screening
  • Genetic testing for inherited cancer risk variants (e.g. BRCA, Lynch)
  • Even carriers without symptoms can act early with targeted health strategies
  • Includes personalized risk report and family guidance
Learn More
Cancer Risk Screening vs. Multi-Cancer Early Detection (MCED) Test
Feature 癌症风险检测 MCED Test
Test Type Inherited genetic test Blood-based tumor signal test
Purpose Predict future cancer risk Detect existing early cancer
Frequency Once (unless new genes are added) Regularly (e.g. yearly)
Results Risk level (e.g., high, moderate) Presence or absence of cancer signal
Recommended Age Groups 18+ 40+
Who is Suitable • Individuals with family cancer history
• People planning preventive measures		 • Adults over 40 (especially without standard screening options)
• Those with family cancer history
• People wanting proactive monitoring
SuperDNA Cancer Risk Screening
  • Genetic testing for inherited cancer risk variants (e.g. BRCA, Lynch)
  • Even carriers without symptoms can act early with targeted health strategies
  • Includes personalized risk report and family guidance
Learn More
Cancer Risk Screening vs. MCED Test
Feature 癌症风险检测 MCED Test
Test Type Inherited genetic test Blood-based tumor signal test
Purpose Predict future cancer risk Detect existing early cancer
Frequency Once (unless new genes are added) Regularly (e.g. yearly)
Results Risk level (e.g., high, moderate) Presence or absence of cancer signal
Recommended Age Groups 18+ 40+
Who is Suitable • Individuals with family cancer history
• People planning preventive measures		 • Adults over 40 (especially without standard screening options)
• Those with family cancer history
• People wanting proactive monitoring

Real Stories & Impact

The test detected a cancer signal—we caught ovarian cancer at Stage I

In a community study of ~53,000 people, MCED testing flagged early-stage cancers including those without regular screening, with 91% correct tissue prediction .

Half the cancers we detected were types we can’t screen for traditionally—and 50% were stage I/II.

PATHFINDER trial showed 71% of detected cancers lacked standard screening; half were early stage.

The signal appeared before symptoms—now I’m in treatment early.”

Johns Hopkins pilot found cancer signs up to three years before symptoms.

Your Genes Hold Clues—Let Us Help You Find Them

Whether you have a family history or want peace of mind—early detection gives you time and choices.
Learn About CancerDetect
Learn About Risk Screening
Select your currency
MYR 马来西亚林吉特
USD 美元
新币 新加坡元（S$）